Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems
Related Experiment Video
Updated: Aug 12, 2025
Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast
Published on: March 30, 2010
Nadja Blasey1, Daria Rehrmann1, Anna Katharina Riebisch1
1Department of Molecular Immunology, Ruhr-University Bochum, Bochum, Germany.
Abstract:
Infections caused by Gram-negative pathogens pose a major health burden. Both respiratory and gastrointestinal infections are commonly associated with these pathogens. With the increase in antimicrobial resistance (AMR) over the last decades, bacterial infections may soon become the threat they have been before the discovery of antibiotics. Many Gram-negative pathogens encode virulence-associated Type III and Type IV secretion systems, which they use to inject bacterial effector proteins across bacterial and host cell membranes into the host cell cytosol, where they subvert host cell functions in favor of bacterial replication and survival. These secretion systems are essential for the pathogens to cause disease, and secretion system mutants are commonly avirulent in infection models. Hence, these structures present attractive targets for anti-virulence therapies. Here, we review previously and recently identified inhibitors of virulence-associated bacterial secretions systems and discuss their potential as therapeutics.
Insights
Gram-negative bacterial infections are a growing threat due to antimicrobial resistance. Targeting their virulence secretion systems offers a promising anti-virulence therapy strategy.
Area of Science:
- Microbiology
- Infectious Diseases
- Drug Discovery
Background:
- Gram-negative bacterial infections cause significant respiratory and gastrointestinal disease burdens.
- Increasing antimicrobial resistance (AMR) necessitates novel therapeutic approaches.
- Type III and Type IV secretion systems are crucial virulence factors in Gram-negative pathogens.
Purpose of the Study:
- To review inhibitors of bacterial Type III and Type IV secretion systems.
- To discuss the therapeutic potential of targeting these essential virulence mechanisms.
Main Methods:
- Literature review of previously and recently identified inhibitors.
- Analysis of the role of secretion systems in bacterial pathogenesis.
Main Results:
- Type III and Type IV secretion systems are essential for Gram-negative pathogen virulence.
- Inhibitors targeting these systems demonstrate potential for anti-virulence therapies.
Conclusions:
- Targeting virulence-associated secretion systems represents a viable anti-virulence strategy.
- Further development of these inhibitors could lead to new treatments for Gram-negative infections.
More Related Videos
Related Concept Videos
01:28Gene Regulation in Microbial Communities: Quorum Sensing
01:17Gram-negative Bacterial Protein Secretion Systems
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:23Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
01:18Surface Membrane Barriers
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
01:28Biological Methods for Microbial Control